EX 1314
Alternative Names: BMS-604992; EX-1314; GHSR agonist - ElixirLatest Information Update: 16 Jul 2016
At a glance
- Originator Bristol-Myers Squibb
- Developer Elixir Pharmaceuticals
- Class Carbamates; Heterocyclic bicyclo compounds; Pyridines; Small molecules; Tetrazoles; Triazoles
- Mechanism of Action Ghrelin agonists; Ghrelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cachexia; Diabetic gastroparesis; Gastrointestinal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cachexia in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic gastroparesis in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (PO)